Kronos Bio Inc KRON Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Nov 17, 2023 (filed on Nov 17, 2023)

Insider Name:

Bischofberger Norbert W

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

97,935

Price:

$1.08
Nov 16, 2023 (filed on Nov 17, 2023)

Insider Name:

Bischofberger Norbert W

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

262,433

Price:

$1.00
Nov 15, 2023 (filed on Nov 17, 2023)

Insider Name:

Bischofberger Norbert W

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

1,370,688

Price:

$0.80
Jul 06, 2023 (filed on Jul 07, 2023)

Insider Name:

Dinsmore Christopher

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-6,634

Price:

$1.75
Jul 06, 2023 (filed on Jul 07, 2023)

Insider Name:

DiMartino Jorge

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-10,818

Price:

$1.75
Jul 06, 2023 (filed on Jul 07, 2023)

Insider Name:

Al-Wakeel Yasir B.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-9,617

Price:

$1.75
Jun 22, 2023 (filed on Jun 26, 2023)

Insider Name:

Ridloff Elena

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

17,000

Price:

--
Jun 22, 2023 (filed on Jun 26, 2023)

Insider Name:

Ridloff Elena

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

11,333

Price:

--
Jun 22, 2023 (filed on Jun 26, 2023)

Insider Name:

Dansey Roger D

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

5,868

Price:

--
Jun 22, 2023 (filed on Jun 26, 2023)

Insider Name:

Stultz Katherine V

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

7,079

Price:

--

Filings by filing date

Nov 17, 2023 (filed on Nov 17, 2023)

Insider Name:

Bischofberger Norbert W

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

97,935

Price:

$1.08
Nov 16, 2023 (filed on Nov 17, 2023)

Insider Name:

Bischofberger Norbert W

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

262,433

Price:

$1.00
Nov 15, 2023 (filed on Nov 17, 2023)

Insider Name:

Bischofberger Norbert W

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

1,370,688

Price:

$0.80
Jul 06, 2023 (filed on Jul 07, 2023)

Insider Name:

Dinsmore Christopher

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-6,634

Price:

$1.75
Jul 06, 2023 (filed on Jul 07, 2023)

Insider Name:

DiMartino Jorge

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-10,818

Price:

$1.75
Jul 06, 2023 (filed on Jul 07, 2023)

Insider Name:

Al-Wakeel Yasir B.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-9,617

Price:

$1.75
Jun 22, 2023 (filed on Jun 26, 2023)

Insider Name:

Ridloff Elena

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

17,000

Price:

--
Jun 22, 2023 (filed on Jun 26, 2023)

Insider Name:

Ridloff Elena

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

11,333

Price:

--
Jun 22, 2023 (filed on Jun 26, 2023)

Insider Name:

Dansey Roger D

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

5,868

Price:

--
Jun 22, 2023 (filed on Jun 26, 2023)

Insider Name:

Stultz Katherine V

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

7,079

Price:

--

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	1300 S. El Camino Real, Suite 400 SAN MATEO CA 94402
Tel:	1-650-7815026
Website:	https://kronosbio.com
IR:	See website

Key People

Norbert W. Bischofberger President, Chief Executive Officer, Director	Sandra A. Gardiner Interim Chief Financial Officer	Barbara A. Kosacz Chief Operating Officer, General Counsel
Jorge Dimartino Executive Vice President - Clinical Development, Chief Medical Officer	Christopher Dinsmore Chief Scientific Officer

Business Overview

Kronos Bio, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics that target the dysregulated transcription that causes cancer and other serious diseases. It focuses on advancing two investigational compounds in clinical trials for patients with cancer. The Company's product engine includes its proprietary small molecule microarray (SMM) screening platform, which provides the capability to map and target transcription regulatory networks (TRNs) in a differentiated manner to enable discovery of novel compounds and improve its ability to discover and optimize clinical development candidates. Its pipeline includes KB-0742 and Lanraplenib. KB-0742 is an oral cyclin dependent kinase 9 (CDK9) inhibitor for the treatment of MYC-amplified and other transcriptionally addicted solid tumors. Lanraplenib is a small molecule selective inhibitor targeting spleen tyrosine kinase (SYK), a critical node in a dysregulated TRN within acute myeloid leukemia (AML).

Financial Overview

For the nine months ended 30 September 2023, Kronos Bio Inc revenues increased from $0K to $4M. Net loss decreased 14% to $87.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Interest income (expense), net increase from $2M to $7.1M (income), Research and development - Balancing val decrease of 8% to $52.5M (expense).

Employees:	99 as of Sep 30, 2023

Reporting Currency:	U.S. Dollars
Enterprise value:	N/A
Annual revenue (TTM):	$4.00M as of Sep 30, 2023
EBITDA (TTM):	-$121.06M as of Sep 30, 2023
Net annual income (TTM):	-$119.14M as of Sep 30, 2023
Free cash flow (TTM):	-$76.79M as of Sep 30, 2023
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	58,316,520 as of Nov 8, 2023
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization